A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...

One in every 8 men in the United States will develop prostate cancer, according to prostate cancer statistics released by the American Cancer Society.

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

Researchers found that late-stage, or distant-stage, prostate cancer is increasing across all age groups, including by approximately 3% annually in men under 55 and by 6% in those 55 and older. The ...

There is widespread misinformation when it comes to prostate cancer. Oncologist Dr Sudipto De debunks 4 myths and stresses the importance of regular screenings.

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...

“As part of a treatment plan for prostate cancer, President Biden is currently undergoing radiation therapy and hormone ...